<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850095</url>
  </required_header>
  <id_info>
    <org_study_id>1622/11</org_study_id>
    <nct_id>NCT01850095</nct_id>
  </id_info>
  <brief_title>The Influence of Peripheral Androgen Conversion at Women Adult Acne</brief_title>
  <official_title>The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Alexandre Dias da Rocha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fleury</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associacao Fundo de Incentivo a Psicofarmcologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of SÃ£o Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous unit. Recent
      studies have demonstrated an increase number of acne cases in adult women. These cases are
      predominantly normoandrogenic and have some clinical differences when compared with the most
      common group, the adolescent. The local glandular metabolism converts some hormonal
      precursors to more active substances that increase the sebum production, leaving these areas
      more prone to increase the colonization to Propionibacterium Acnes (P. Acnes). Toll-like
      receptor 2, expressed by inflammatory cells play a crucial role in the innate immune response
      to this bacterium. Previous studies confirm that exist a reduced expression of CD1d by
      keratinocytes in acne lesion, what can be interpreted as a low antigen-present function. The
      influence of hormonal alteration in the sebaceous glands could modulate the expressions of
      TLR-2 and CD1d explaining the persistence of lesions in adult women. The change to more
      estrogenic metabolism, with use of specific contraceptive pills could normalize this
      immune-mediated inflammatory process.

      Objective

      To analyze how the peripheral androgen conversion can influence the toll-like receptor 2 and
      CD1d expression in women with inflammatory acne before and after 6 months of oral
      contraceptives with anti-androgen activity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evaluation of the treatment group</measure>
    <time_frame>6 months</time_frame>
    <description>by the researcher: by counting the inflammatory lesions. by the research subjects: the general appearance of skin at the time of study entry and after the treatment. Will be used a 4-point scale: 0 = no acne, 1 = mild acne, moderate acne, and 2 = 4 = severe acne.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photographic study of the treatment group</measure>
    <time_frame>6 months</time_frame>
    <description>This evaluation will be performed by two independent dermatologists, the degree of change in the intensity of acne, comparing the pre and post treatment photos through a 5-point scale: -2 = much worse, -1 = worse, 0 = unchanged; +1 = better, +2 = much better.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Application of the questionnaire index of quality of life in Acne</measure>
    <time_frame>6 months</time_frame>
    <description>AcneQol (Girman et al, 1996, Martin et al, 2001, Fehnel et al, 2003),</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemical analysis with quantitative digital blind:</measure>
    <time_frame>6 months</time_frame>
    <description>For immunohistochemistry will be used the following markers:
a polyclonal rabbit anti-TLR2 (ABBIOTEC 251,110) Biogen, Brazil.
mouse monoclonal anti-CD1d, clone NOR3.2 (Genway 20-272-1903). Biogen, Brazil.
Statistical comparisons are made between the following groups: control group 2 and the region with inflammatory lesions in the treatment group, region and region inflammatory non-inflammatory group of medications and treatment before inflammatory region before and after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serological blood measurements</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of serological blood measurements of free and total testosterone, dihydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and androsterone glucuronide, before and after the treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acne</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical acid azelaic, used 2 times a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contraceptive with drospirenone/ethinyl estradiol used for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group ( only take biopsies and blood samples )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment azelaic acid (azelan)</intervention_name>
    <description>treatment for 6 months</description>
    <arm_group_label>treatment 1</arm_group_label>
    <other_name>azelaic acid (azelan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorspirenone/ethynil estradiol</intervention_name>
    <arm_group_label>treatment 2</arm_group_label>
    <other_name>(yaz)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To all:

          1. Signing the consent form before any study procedures;

          2. women aged 26 to 44 years, not pregnant and in good health;

          3. no topical treatment for acne in the past three months,

          4. absence of the use of oral antibiotics in the last 3 months;

          5. absence of the use of isotretinoin in the last 2 years;

          6. absence of oral contraceptive use in the last 3 months;

          7. absence of clinical evidence of immunosuppression and

          8. accordance with the conditions of study, ability to understand and strictly follow the
             instructions given.

        For the oral contraceptives group:

          1. No contraindications to the use hormonal contraceptives.

        For the azelaic acid group:

          1. Absence of hypersensitivity to azelaic acid.

        Exclusion Criteria:

        For all

          1. Women who do not agree with the conditions of the study or without the ability to
             understand and closely follow the guidelines received without availability to attend
             the revaluations or who refuse to sign the Informed Consent Form;

          2. pregnant or lactating women;

          3. use of the following oral medications: cortisone derivatives, lithium,
             anticonvulsants, isoniazid, oral contraceptives, androgens, danazol, iodides,
             bromides, disulfiram, cyclosporine, azathioprine, thiuram, vitamins B2, B6 and B12;

          4. treatment of facial skin with topical retinoids (tretinoin and adapalene), azelaic
             acid, benzoyl peroxide, clindamycin, erythromycin, nicotinamina, alone or in
             combination, in the past 3 months;

          5. treatment with oral antibiotics in the past 3 months;

          6. acnogenics cosmetics.

        For the group treated with oral contraceptives:

        1. Presence of contraindications to oral contraceptive use:

          1. Smokers over 35 years;

          2. history of deep venous thrombosis;

          3. history of stroke;

          4. history of breast cancer;

          5. presence of jaundice, and severe active liver disease or biliary disease;

          6. diabetes mellitus for more than 20 years or eye injury, or neurological impairment;

          7. blood pressure greater than or equal to 160 to 100 for systolic and diastolic;

          8. cardiovascular disease and

          9. presence of severe headache associated with blurred vision frequently.

        For the group treated with azelaic acid:

        1.Presense of allergic and / or irritating symptoms to the use of azelaic acid.

        For the control group 1:

        1. History, clinical signs and / or laboratory evidence of hyperandrogenism. 2 .Presence of
        inflammatory acne.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marco rocha, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIFESP-EPM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>marco rocha, md</last_name>
    <phone>55-11-55799331</phone>
    <email>marcoderm@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal University of SÃ£o Paulo-Dermatology</name>
      <address>
        <city>sÃ£o Paulo</city>
        <zip>04038-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>marco rocha, md</last_name>
      <phone>55-11-55799331</phone>
      <email>marcoderm@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>marco rocha, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>edileia bagatin, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009 Jul;8(7):615-8.</citation>
    <PMID>19588637</PMID>
  </reference>
  <reference>
    <citation>Shen Y, Wang T, Zhou C, Wang X, Ding X, Tian S, Liu Y, Peng G, Xue S, Zhou J, Wang R, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. Acta Derm Venereol. 2012 Jan;92(1):40-4. doi: 10.2340/00015555-1164.</citation>
    <PMID>21710106</PMID>
  </reference>
  <reference>
    <citation>Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37. Review.</citation>
    <PMID>12833004</PMID>
  </reference>
  <reference>
    <citation>Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004 Sep-Oct;22(5):419-28. Review.</citation>
    <PMID>15556729</PMID>
  </reference>
  <reference>
    <citation>Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009 Oct;18(10):821-32. doi: 10.1111/j.1600-0625.2009.00890.x. Epub 2009 Jun 23. Review.</citation>
    <PMID>19555434</PMID>
  </reference>
  <reference>
    <citation>White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S34-7.</citation>
    <PMID>9703121</PMID>
  </reference>
  <reference>
    <citation>Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999 Oct;41(4):577-80.</citation>
    <PMID>10495379</PMID>
  </reference>
  <reference>
    <citation>Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997 Jan;136(1):66-70.</citation>
    <PMID>9039297</PMID>
  </reference>
  <reference>
    <citation>Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):541-5.</citation>
    <PMID>11843213</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of SÃ£o Paulo</investigator_affiliation>
    <investigator_full_name>Marco Alexandre Dias da Rocha</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>adult</keyword>
  <keyword>women</keyword>
  <keyword>TLR</keyword>
  <keyword>CD1d</keyword>
  <keyword>androgens</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

